Tanaproget
Alternative Name: NSP-989; NSP-989 COMBO; Tanaproget COMBO; WAY-166989
Description: Tanaproget (NSP-989) is a novel, non-steroidal, high affinity, high efficacy, and very selective progesterone receptor agonist. Due to its much more selective binding profile relative to most conventional, steroidal progestins, tanaproget may prove to produce fewer side effects in comparison.
Product Details
Duration: One day
Regimen:
Dose: Doses of 0.01, 0.03, 0.1, 0.3, and 1mg of tanaproget were studied.
Active Pharmaceutical Ingredient (API):
Status Details
Began discovery in: Prior to 2005
Status Details: - Sublicensed to Pfizer in 2010.
- Sublicensed to Pfizer in 2010.
Additional Information
References: Zhang Z, et al. (2005). Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J. Biol. Chem. 280 (31): 28468-75.
Bapst JL, et al. (2006) Pharmacokinetics and safety of tanaproget, a nonsteroidal progesterone receptor agonist, in healthy women. Contraception. 74 (5): 414-8.
Ligand Pharmaceuticals, Inc. website: http://www.ligand.com/
Zhang Z, et al. (2005). Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J. Biol. Chem. 280 (31): 28468-75.
Bapst JL, et al. (2006) Pharmacokinetics and safety of tanaproget, a nonsteroidal progesterone receptor agonist, in healthy women. Contraception. 74 (5): 414-8.
Ligand Pharmaceuticals, Inc. website: http://www.ligand.com/